Clinical Trial Update: A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants [Phase 3]

View source ↗

Summary

A completed Phase 3 study evaluating TVP-1012 (1 mg) in levodopa-treated Parkinson's disease patients; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• TVP-1012

Snippet

Sponsor: Takeda | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-04-19